CNBX
CNBX Pharmaceuticals Inc.
Price Chart
Latest Quote
$0.00
-0.00 (-25.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 1 |
Stock Information
| Shares Outstanding | 1.23B |
| Total Debt | $1.17M |
| Cash Equivalents | $12K |
| Net Income | $-368K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $184K |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.40M |
| Income | $-368K |
| Book/sh | $-0.00 |
| Cash/sh | $0.00 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 0.01 |
| Current Ratio | 0.01 |
Returns & Margins
| ROA | -585.51% |
Ownership
| Insider Ownership | 0.06% |
| Institutional Ownership | 8.16% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.07 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 40.00 |
| ATR | 0.0001 |
| Shares Float | 1.23B |
| Volatility | 0.67 |
| Rel Volume | 7.49 |
Performance History
| Week | +0.00% |
| Month | -25.00% |
| Quarter | +0.00% |
| 6 Months | -62.50% |
| YTD | -62.50% |
| Year | -85.00% |
| 3 Years | -99.30% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.00 | 119,716,783 |
| 2026-06-16 | $0.00 | 100,017 |
| 2026-06-15 | $0.00 | 6,563,102 |
| 2026-06-12 | $0.00 | 17,499,838 |
| 2026-06-11 | $0.00 | 25,092 |
| 2026-06-10 | $0.00 | 2,010,550 |
| 2026-06-09 | $0.00 | 0 |
| 2026-06-08 | $0.00 | 3,610,023 |
| 2026-06-05 | $0.00 | 20,007 |
| 2026-06-04 | $0.00 | 2,010 |
| 2026-06-03 | $0.00 | 2,165,014 |
| 2026-06-02 | $0.00 | 1,252,184 |
| 2026-06-01 | $0.00 | 9,977,963 |
| 2026-05-29 | $0.00 | 5,571,352 |
| 2026-05-28 | $0.00 | 12,108,551 |
| 2026-05-27 | $0.00 | 60,582,108 |
| 2026-05-26 | $0.00 | 10,583,369 |
| 2026-05-22 | $0.00 | 2,375,042 |
| 2026-05-21 | $0.00 | 13,328,379 |
| 2026-05-20 | $0.00 | 52,061,870 |
| 2026-05-19 | $0.00 | 13,407,217 |
| 2026-05-18 | $0.00 | 14,850,051 |
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
đ° Latest News
No news articles available at the moment. Check back later for updates on CNBX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $130,074 | $410,165 | $29,958 |
| Operating Revenue | $0 | $130,074 | $410,165 | $29,958 |
| Expenses | ||||
| Interest Expense | $40,189 | $19,611 | $1,174 | $1,273 |
| Total Expenses | $271,691 | $713,214 | $1,341,545 | $2,983,928 |
| Other Income Expense | $-2,096 | $-92,447 | $-2,722,870 | $-1,437,138 |
| Net Non Operating Interest Income Expense | $-40,189 | $-19,611 | $-55,984 | $-1,273 |
| Interest Expense Non Operating | $40,189 | $19,611 | $1,174 | $1,273 |
| Operating Expense | $271,691 | $713,214 | $1,341,545 | $2,983,928 |
| General And Administrative Expense | $271,691 | $518,426 | $908,757 | $1,784,670 |
| Selling And Marketing Expense | - | $0 | $1,223 | $15,977 |
| Other Non Operating Income Expenses | - | - | $-54,810 | $-722,236 |
| Total Other Finance Cost | - | - | $54,810 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Net Interest Income | $-40,189 | $-19,611 | $-55,984 | $-1,273 |
| Normalized Income | $-311,880 | $-602,751 | $-987,364 | $-3,677,479 |
| Net Income From Continuing And Discontinued Operation | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Total Operating Income As Reported | $-271,691 | $-583,139 | $-931,380 | $-2,953,970 |
| Net Income Common Stockholders | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Net Income | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Net Income Including Noncontrolling Interests | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Net Income Continuous Operations | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Pretax Income | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Special Income Charges | $0 | $-88,934 | $-2,726,231 | $-656,331 |
| Operating Income | $-271,691 | $-583,140 | $-931,380 | $-2,953,970 |
| Per Share | ||||
| Diluted EPS | $0.00 | $-0.02 | $-0.42 | $-3.59 |
| Basic EPS | $0.00 | $-0.02 | $-0.42 | $-3.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-271,691 | $-510,820 | $-824,129 | $-3,477,679 |
| Total Unusual Items | $-2,096 | $-92,447 | $-2,722,870 | $-714,902 |
| Total Unusual Items Excluding Goodwill | $-2,096 | $-92,447 | $-2,722,870 | $-714,902 |
| Reconciled Depreciation | $0 | $72,320 | $162,061 | $198,527 |
| EBITDA (Bullshit earnings) | $-273,787 | $-603,267 | $-3,546,999 | $-4,192,581 |
| EBIT | $-273,787 | $-675,587 | $-3,709,060 | $-4,391,108 |
| Diluted Average Shares | $90,649,474 | $30,247,691 | $8,824,636 | $1,222,641 |
| Basic Average Shares | $90,649,474 | $30,247,691 | $8,824,636 | $1,222,641 |
| Diluted NI Availto Com Stockholders | $-313,976 | $-695,198 | $-3,710,234 | $-4,392,381 |
| Gain On Sale Of Ppe | $0 | $-88,934 | $-2,726,231 | $-656,331 |
| Gain On Sale Of Security | $-2,096 | $-3,513 | $3,361 | $-58,571 |
| Research And Development | $0 | $194,788 | $431,565 | $1,183,281 |
| Selling General And Administration | $271,691 | $518,426 | $909,980 | $1,800,647 |
| Other Gand A | $134,031 | $-1,813 | $198,624 | $582,990 |
| Insurance And Claims | $0 | $32,410 | $68,278 | $93,192 |
| Salaries And Wages | $137,660 | $487,829 | $641,855 | $1,108,488 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Total Assets | $18,437 | $31,383 | $499,039 | $811,166 |
| Total Non Current Assets | $0 | $0 | $274,731 | $612,879 |
| Current Assets | $18,437 | $31,383 | $224,308 | $198,287 |
| Receivables | $3,326 | $4,967 | $94,612 | $80,772 |
| Other Receivables | $3,326 | $4,967 | $94,612 | $80,772 |
| Cash Cash Equivalents And Short Term Investments | $15,111 | $26,416 | $129,696 | $117,515 |
| Cash And Cash Equivalents | $15,111 | $26,416 | $129,696 | $117,515 |
| Cash Financial | $15,111 | $26,416 | $129,696 | $117,515 |
| Investmentin Financial Assets | - | $0 | $0 | $176,087 |
| Prepaid Assets | - | - | - | $80,772 |
| Other Current Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,182,146 | $1,268,691 | $1,213,888 | $1,641,187 |
| Total Debt | $1,197,257 | $1,295,107 | $1,343,584 | $1,758,702 |
| Current Debt And Capital Lease Obligation | $1,197,257 | $1,295,107 | $1,343,584 | $1,758,702 |
| Current Debt | $1,197,257 | $1,295,107 | $1,343,584 | $1,758,702 |
| Other Current Borrowings | $1,197,257 | $1,295,107 | $1,343,584 | $1,758,702 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,514,730 | $2,511,363 | $2,516,328 | $2,443,477 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $2 |
| Current Liabilities | $2,514,730 | $2,511,363 | $2,516,328 | $2,443,475 |
| Payables And Accrued Expenses | $1,317,473 | $1,216,256 | $1,172,744 | $684,773 |
| Payables | $1,317,473 | $1,216,256 | $1,172,744 | $684,773 |
| Accounts Payable | $49,252 | $40,841 | $335,915 | $461,128 |
| Equity | ||||
| Common Stock Equity | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Total Equity Gross Minority Interest | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Stockholders Equity | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Retained Earnings | $-25,268,376 | $-24,954,400 | $-24,259,202 | $-20,548,968 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $0 | $-2,574,846 |
| Other Equity Interest | - | - | - | $3,459,510 |
| Other Equity Adjustments | - | - | - | $-2,574,846 |
| Other | ||||
| Ordinary Shares Number | $553,962,206 | $31,111,352 | $22,611,352 | $1,257,927 |
| Share Issued | $553,962,206 | $31,111,352 | $22,611,352 | $1,257,927 |
| Tangible Book Value | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Invested Capital | $-1,299,036 | $-1,184,873 | $-673,705 | $126,391 |
| Working Capital | $-2,496,293 | $-2,479,980 | $-2,292,020 | $-2,245,188 |
| Total Capitalization | $-2,496,293 | $-2,479,980 | $-2,017,289 | $-1,632,311 |
| Additional Paid In Capital | $22,716,687 | $22,471,309 | $22,239,652 | $18,031,869 |
| Capital Stock | $55,396 | $3,111 | $2,261 | $124 |
| Common Stock | $55,396 | $3,111 | $2,261 | $124 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | $1,268,221 | $1,175,415 | $836,829 | $223,645 |
| Net PPE | $0 | $0 | $274,731 | $436,792 |
| Investments And Advances | - | $0 | $0 | $176,087 |
| Treasury Shares Number | - | - | $0 | - |
| Available For Sale Securities | - | - | - | $176,087 |
| Accumulated Depreciation | - | - | - | - |
| Gross PPE | - | - | - | - |
| Machinery Furniture Equipment | - | - | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-171,305 | $-245,465 | $-112,521 | $-1,680,848 |
| Operating Activities | ||||
| Operating Cash Flow | $-171,305 | $-244,269 | $-112,521 | $-1,679,192 |
| Cash Flow From Continuing Operating Activities | $-171,305 | $-244,269 | $-112,521 | $-1,679,192 |
| Operating Gains Losses | - | $88,934 | $2,726,232 | $-12,800 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $113,477 | $24,702 | $25,229 |
| Cash Flow From Continuing Investing Activities | $0 | $113,477 | $24,702 | $25,229 |
| Capital Expenditure | - | $-1,196 | - | $-1,656 |
| Financing Activities | ||||
| Financing Cash Flow | $160,000 | $27,512 | $100,000 | $389,858 |
| Cash Flow From Continuing Financing Activities | $160,000 | $27,512 | $100,000 | $389,858 |
| Other | ||||
| Issuance Of Debt | $160,000 | $27,512 | $100,000 | $389,858 |
| End Cash Position | $15,111 | $26,416 | $129,696 | $117,515 |
| Beginning Cash Position | $26,416 | $129,696 | $117,515 | $1,386,473 |
| Changes In Cash | $-11,305 | $-103,280 | $12,181 | $-1,264,105 |
| Net Issuance Payments Of Debt | $160,000 | $27,512 | $100,000 | $389,858 |
| Net Short Term Debt Issuance | $160,000 | $27,512 | $100,000 | $389,858 |
| Short Term Debt Issuance | $160,000 | $27,512 | $100,000 | $389,858 |
| Net PPE Purchase And Sale | $0 | $113,477 | $0 | $25,229 |
| Sale Of PPE | $0 | $114,673 | $0 | $26,885 |
| Purchase Of PPE | $0 | $-1,196 | $0 | $-1,656 |
| Change In Working Capital | $102,858 | $133,157 | $474,129 | $407,226 |
| Change In Payables And Accrued Expense | $101,217 | $43,513 | $487,969 | $283,623 |
| Change In Receivables | $1,641 | $89,644 | $-13,840 | $123,603 |
| Changes In Account Receivables | $1,641 | $89,644 | $-13,840 | $123,603 |
| Other Non Cash Items | $39,813 | $16,798 | $54,811 | $722,236 |
| Stock Based Compensation | $0 | $139,720 | $180,480 | $728,869 |
| Depreciation Amortization Depletion | $0 | $72,320 | $162,061 | $198,527 |
| Depreciation And Amortization | $0 | $72,320 | $162,061 | $198,527 |
| Depreciation | $0 | $72,320 | $162,061 | $198,527 |
| Gain Loss On Sale Of PPE | $0 | $88,934 | $2,726,232 | $-12,800 |
| Net Income From Continuing Operations | $-313,976 | $-695,198 | $-3,710,234 | $-3,723,250 |
| Net Investment Purchase And Sale | - | $0 | $24,702 | $0 |
| Sale Of Investment | - | $0 | $24,702 | $0 |
| Effect Of Exchange Rate Changes | - | - | $0 | $-4,853 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-02-02